Relation of left ventricular ejection fraction and functional capacity with metabolism and inflammation in chronic heart failure with reduced ejection fraction (from the MIMICA Study).

[1]  T. Fahey,et al.  Association between allopurinol and mortality in heart failure patients: a long‐term follow‐up study , 2009, International journal of clinical practice.

[2]  J. Burnett,et al.  A new role for the natriuretic peptides: metabolic regulators of the adipocyte. , 2009, Journal of the American College of Cardiology.

[3]  G. Fonarow,et al.  Albumin levels predict survival in patients with systolic heart failure. , 2008, American heart journal.

[4]  B. Howard,et al.  Prognostic implications of relations of left ventricular systolic dysfunction with body composition and myocardial energy expenditure: the Strong Heart Study. , 2008, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[5]  J. Niebauer.  Effects of exercise training on inflammatory markers in patients with heart failure , 2008, Heart Failure Reviews.

[6]  S. Ogawa,et al.  Effects of β-Blocker Therapy on High Sensitivity C-Reactive Protein, Oxidative Stress, and Cardiac Function in Patients With Congestive Heart Failure , 2007 .

[7]  B. Meier,et al.  Cytokine activation and disease progression in patients with stable moderate chronic heart failure. , 2007, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[8]  John G F Cleland,et al.  Relationship of high-sensitivity C-reactive protein to prognosis and other prognostic markers in outpatients with heart failure. , 2007, American heart journal.

[9]  J. McMurray,et al.  Increase in serum adiponectin concentration in patients with heart failure and cachexia: relationship with leptin, other cytokines, and B-type natriuretic peptide. , 2007, European heart journal.

[10]  P. Ponikowski,et al.  Anabolic Deficiency in Men With Chronic Heart Failure: Prevalence and Detrimental Impact on Survival , 2006, Circulation.

[11]  E. Colín-Ramírez,et al.  Body composition and echocardiographic abnormalities associated to anemia and volume overload in heart failure patients. , 2006, Clinical nutrition.

[12]  S. Bandinelli,et al.  Uric acid and inflammatory markers. , 2006, European heart journal.

[13]  N. Uszko‐Lencer,et al.  Measuring body composition in chronic heart failure: A comparison of methods , 2006, European journal of heart failure.

[14]  Pål Aukrust,et al.  Systemic inflammation in heart failure – The whys and wherefores , 2006, Heart Failure Reviews.

[15]  J. Ornato,et al.  ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult—Summary Article , 2005 .

[16]  A. Struthers,et al.  Allopurinol reduces B-type natriuretic peptide concentrations and haemoglobin but does not alter exercise capacity in chronic heart failure , 2005, Heart.

[17]  G. Schuler,et al.  Aging and heart failure--similar syndromes of exercise intolerance? Implications for exercise-based interventions. , 2005, Heart failure monitor.

[18]  L. D. Libera,et al.  Muscle wastage in chronic heart failure, between apoptosis, catabolism and altered anabolism: a chimaeric view of inflammation? , 2004, Current opinion in clinical nutrition and metabolic care.

[19]  Stephan von Haehling,et al.  Inflammatory mediators in chronic heart failure: an overview , 2004, Heart.

[20]  R. Troughton,et al.  NT‐proBNP in heart failure: therapy decisions and monitoring , 2004, European journal of heart failure.

[21]  R. Turner,et al.  Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.

[22]  G. Gensini,et al.  Prognostic value of 6‐minute walk corridor test in patients with mild to moderate heart failure: comparison with other methods of functional evaluation , 2003, European journal of heart failure.

[23]  Abdissa Negassa,et al.  Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study , 2003, The Lancet.

[24]  J. Alonso-Martínez,et al.  C‐reactive protein as a predictor of improvement and readmission in heart failure , 2002, European journal of heart failure.

[25]  S. Verma,et al.  Endothelin Antagonism and Interleukin-6 Inhibition Attenuate the Proatherogenic Effects of C-Reactive Protein , 2002, Circulation.

[26]  J. Kjekshus,et al.  Effect of metoprolol on cytokine levels in chronic heart failure--a substudy in the Metoprolol Controlled-Release Randomised Intervention Trial in Heart Failure (MERIT-HF). , 2001, American heart journal.

[27]  P. Ponikowski,et al.  The relationship of the erythrocyte sedimentation rate to inflammatory cytokines and survival in patients with chronic heart failure treated with angiotensin-converting enzyme inhibitors. , 2000, Journal of the American College of Cardiology.

[28]  K. Nakao,et al.  The plasma levels of dehydroepiandrosterone sulfate are decreased in patients with chronic heart failure in proportion to the severity. , 2000, The Journal of clinical endocrinology and metabolism.

[29]  C. Berry,et al.  Catabolism in chronic heart failure. , 2000, European heart journal.

[30]  Friberg,et al.  Serum leptin levels in heart failure patients may be altered differently according to clinical stage. , 2000, European heart journal.

[31]  S. Anker,et al.  Tumor necrosis factor and steroid metabolism in chronic heart failure: possible relation to muscle wasting. , 1997, Journal of the American College of Cardiology.